Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Latest Articles

  • DroneShield Boosts Defence Capability with $13 Million Adelaide R&D Investment
    DroneShield Boosts Defence Capability with $13 Million Adelaide R&D Investment
    • News

  • Stakk Secures T-Mobile Contract to Power Super App Expansion
    Stakk Secures T-Mobile Contract to Power Super App Expansion
    • News

  • Medibank Backs Emyria with Landmark Depression Care Deal
    Medibank Backs Emyria with Landmark Depression Care Deal
    • News

  • NoviqTech Launches Quantum Intelligence Products, Opening Path to Enterprise-Grade Quantum AI
    NoviqTech Launches Quantum Intelligence Products, Opening Path to Enterprise-Grade Quantum AI
    • News

  • BRE Wins Final Permit to Advance Rare Earth Pilot Plant in Brazil
    BRE Wins Final Permit to Advance Rare Earth Pilot Plant in Brazil
    • News

  • Harris Technology eyes profitability as refurbished tech sales surge
    Harris Technology eyes profitability as refurbished tech sales surge
    • News

  • QIC Fund Backs Ark Mines with $4.5m to Accelerate Sandy Mitchell Development
    • News

  • Swift Secures $2.4m Chevron Contract to Extend Entertainment and Support Services
    Swift Secures $2.4m Chevron Contract to Extend Entertainment and Support Services
    • News

  • FBR’s tech could help reduce housing construction-related cost pressures
    FBR’s tech could help reduce housing construction-related cost pressures
    • News

  • Atomo Locks in US$410K Pascal Order as FebriDx Demand Accelerates in the US
    Atomo Locks in US$410K Pascal Order as FebriDx Demand Accelerates in the US
    • News

Mosquitoes suck. Island Pharmaceuticals does not.

  • In News
  • May 19, 2021
  • Samantha Freidin
Mosquitoes suck. Island Pharmaceuticals does not.

Fun fact: The word mosquito actually translates to “little fly” in Spanish. Although you’re more likely to hear them called a whole host of profanities in many households.

Little f***ers.

If the blood sucking pests weren’t annoying enough, they carry diseases like dengue fever. An estimated 390 million people are infected with dengue each year.

What was once a disease of developing countries is spreading. With the rise of global warming, mosquitoes carrying dengue are travelling further. In recent years there has been a rise in reported cases in Florida, USA and North Queensland. Prolific case numbers were also noted amongst ‘fly in, fly out’ workers in Western Australian mining industry.

Currently there is no treatment for mosquito borne viruses. Australian antiviral drug development company, Island Pharmaceuticals (ASX: ILA) is working to change this by repurposing existing drugs for the treatment of mosquito borne viruses. Their lead program is the development of ISLA-101, a drug with a well known safety profile for antiviral use.

The Company has announced that they have been granted a patent relating to the drug by the United States Patent and Trademark Office. The patent grant was issued on May 18th. Island has licensed the IP portfolio generated by Monash University.

Dr Paul MacLeman, Executive Chairman of Island Pharmaceuticals said “Mosquito borne viruses, such as dengue, Zike and others represent major unmet medical needs throughout the world and about 3 billion people- or 40% of the world’s population- live in areas with a risk of dengue.”

“Having an allowed patent that protects Island’s lead program in this large market provides protection for the development of ISLA-10 and further underpins our ability to advance the program in the US- a key target market.”

ISLA-101 is advancing towards a Phase 2 clinical trial in people with dengue. Should the drug obtain FDA approval and meet other certain criteria, the drug may be eligible for a ‘Priority Review Voucher” which will expedite the approval process for the new drug.

Island listed on the ASX in mid-April of this year after an oversubscribed $7.5 million IPO at a $0.25 Offer Price.

  • About
  • Latest Posts
Samantha Freidin
Samantha Freidin is a business journalist at Emerald Financial whilst also completing a Masters of Marketing and Digital Communications at Monash University.
Latest posts by Samantha Freidin (see all)
  • Parkinson’s UK backs Pharmaxis with $5 million to slow the onset of incurable disease with ‘ground breaking’ trial - September 1, 2022
  • How this company is developing medtech to support Indigenous community health - August 22, 2022
  • A round of ap-paws for PharmAust, changing the ruff prognosis for dogs with lymphoma - August 17, 2022
  •  
  •  
  •  
  •  
  • asx ila
  • dengue
  • ila
  • IPO
  • island pharmaceuticals
  • monash university
  • mosquito diseases
  • paul macleman
  • zike
  • News

Leave a Comment

You must be logged in to post a comment.

  • About
  • Latest Posts
Samantha Freidin
Samantha Freidin is a business journalist at Emerald Financial whilst also completing a Masters of Marketing and Digital Communications at Monash University.
Latest posts by Samantha Freidin (see all)
  • Parkinson’s UK backs Pharmaxis with $5 million to slow the onset of incurable disease with ‘ground breaking’ trial - September 1, 2022
  • How this company is developing medtech to support Indigenous community health - August 22, 2022
  • A round of ap-paws for PharmAust, changing the ruff prognosis for dogs with lymphoma - August 17, 2022

Login or register for free to access unlimited reading

Register Now!
  • About
  • Latest Posts
Samantha Freidin
Samantha Freidin is a business journalist at Emerald Financial whilst also completing a Masters of Marketing and Digital Communications at Monash University.
Latest posts by Samantha Freidin (see all)
  • Parkinson’s UK backs Pharmaxis with $5 million to slow the onset of incurable disease with ‘ground breaking’ trial - September 1, 2022
  • How this company is developing medtech to support Indigenous community health - August 22, 2022
  • A round of ap-paws for PharmAust, changing the ruff prognosis for dogs with lymphoma - August 17, 2022
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.